Inhibrx reports first clinical win for long-elusive immunotherapy target

Inhibrx announced a positive result for its immunotherapy candidate targeting a previously intractable molecular target, marking a first in a field marked by repeated failures. The claim rests on company disclosures, with independent verification pending. If confirmed, this could unlock a new class of cancer treatments and reshape competitive dynamics in immuno-oncology.